There are a few things that I would do if I were to take over control of the company, which would help the situation here quite a bit because it is not generating revenue:
1) I would delay the phase I trial in MMD until funds are in excess. First of all, scientifically, there is no strong evidence its going to give overwhelmingly positive efficacy. The last thing we need is to spend money on something we can't prove works. The market is of significant size in terms of people to run a company, but the Asian population demographic is soft in terms of ability to generate revenue as their salaries are still far behind the western norm. So why spend extra money and time and effort working on that when there is already evidence that there is efficacy with AMD, and it makes absolutely no sense to target this for a functional market to drive a company's revenue stream. It is a supplementary "feel-good" product.
2) SMD is a great phase I trial, but the patient population is not enough to generate a significant amount of money to run the type of company that the AMD population would drive with its market. So generally speaking I would stop with phase I on this study, or delay it and run as small of a phase 2 study as possible to conserve funds for the big gun of AMD. The efficacy is great, its working, and its a nice confirmation of the technology. But at this point its a waste of money to invest in this 100K patient population until we have excess funds for borderline compassionate-use sized markets.
3) I would accelerate the AMD trial by moving it forward as far as possible, and move up the timelines for gathering data by gerrymandering the patient population as much as possible (i.e. do whatever it takes to make sure you get that up and running as fast as possible with interim data publication accelerated if possible). This is the BIG GUN. BUMP THE BIG GUN FORWARD. Streamline it with as few patients as FDA will allow.
4) Ride on Lincoln as long as possible without diluting. Make any new investors pay ahead of the game, like the stock market at large does. You gotta pay to play. The longer we take this alone, the more its worth. Period.
5) Clean up the data from phase 1 so that average scientific type business minds can clearly understand the difference between treated and untreated eyes, and add standard error bars to the graphs for the statisticians to confirm to the regulatory scientists this data is compiled correctly.
Oh WAIT! My bad, after reading this 8K the company did these things. Except for the error bars! FULL STEAM AHEAD all HAIL the CEO and TEAM!
AI
